Planchon P, Magnien V, Beaupain R, Mainguene C, Ronco G, Villa P, Brouty-Boye D
Institut d'Oncologie Cellulaire et Moléculaire Humaine, Hôpital Avicenne, Bobigny, France.
In Vivo. 1992 Nov-Dec;6(6):605-10.
The antiproliferative and cytodifferentiating effects of a new stable butyric derivative, monobut-3, were compared using human MDA-MB-231 breast cancer cells grown in three dimension as either in vitro tumor nodules or in vivo xenograft tumors. In in vitro tumor nodules, monobut-3 exhibited marked growth inhibitory effects consistent with the results obtained in monolayer cell cultures. Some functional cell differentiation was also detected in treated nodules. In in vivo xenografts, monobut-3 significantly decreased MDA-MB-231 tumor take but did not affect the rate of tumor growth. No difference was noted in the histological characteristics of the xenografts between untreated and treated mice. Moreover, once monobut-3 treatment was discontinued, tumor growth rapidly resumed in tumor-free animals. The decreased efficacy of monobut-3 in in vivo MDA-MB-231 xenografts as compared to in vitro tumor nodules indicates that factors related to host environment may still limit the clinical effectiveness of this compound.
使用在三维空间中生长的人MDA-MB-231乳腺癌细胞，以体外肿瘤结节或体内异种移植肿瘤的形式，比较了一种新型稳定丁酸衍生物monobut-3的抗增殖和细胞分化作用。在体外肿瘤结节中，monobut-3表现出显著的生长抑制作用，这与单层细胞培养中获得的结果一致。在处理过的结节中也检测到了一些功能性细胞分化。在体内异种移植中，monobut-3显著降低了MDA-MB-231肿瘤的接种成功率，但不影响肿瘤生长速度。未处理和处理过的小鼠之间的异种移植组织学特征没有差异。此外，一旦停止monobut-3治疗，无肿瘤动物中的肿瘤生长迅速恢复。与体外肿瘤结节相比，monobut-3在体内MDA-MB-231异种移植中的疗效降低，表明与宿主环境相关的因素可能仍然限制了该化合物的临床有效性。
